Phio Pharmaceuticals Corp. (PHIO)
NASDAQ: PHIO · Real-Time Price · USD
1.760
+0.020 (1.15%)
At close: Dec 20, 2024, 4:00 PM
1.660
-0.100 (-5.68%)
After-hours: Dec 20, 2024, 7:57 PM EST
Phio Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
9
Market Cap
1.86M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
cbdMD | 19.48M |
Scorpius Holdings | 10.04M |
Akanda | 2.51M |
Tivic Health Systems | 957.00K |
Helius Medical Technologies | 502.00K |
IMAC Holdings | -1.33M |
PHIO News
- 2 days ago - Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Newsfile Corp
- 2 days ago - Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762 - Newsfile Corp
- 9 days ago - Phio Pharmaceuticals Announces Publication in Frontiers in Immunology - Newsfile Corp
- 11 days ago - Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award - Newsfile Corp
- 18 days ago - Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Newsfile Corp
- 4 weeks ago - Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study - Newsfile Corp
- 5 weeks ago - Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - Newsfile Corp
- 6 weeks ago - Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - Newsfile Corp